Evidence map›Paper›PMID 29796287›Full record

ArticleAsthma research and practice2018

Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms.

Ryosuke Souma, Kumiya Sugiyama, Hiroyuki Masuda, Hajime Arifuku, Kentaro Nakano, Hiroyoshi Watanabe, Tomoshige Wakayama, Shingo Tokita, Masamitsu Tatewaki, Hideyuki Satoh and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asthma research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ryosuke Souma1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Kumiya Sugiyama1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.ORCID 0000-0002-0624-946X
Hiroyuki Masuda1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Hajime Arifuku1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Kentaro Nakano1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Hiroyoshi Watanabe1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Tomoshige Wakayama1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Shingo Tokita1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Masamitsu Tatewaki1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Hideyuki Satoh1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Kenya Koyama1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Yumeko Hayashi2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kita-kobayashi, Mibu, Tochigi 321-0293 Japan.
Fumiya Fukushima2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kita-kobayashi, Mibu, Tochigi 321-0293 Japan.
Hirokuni Hirata1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.
Masafumi Arima3Department of Rheumatology, Dokkyo Medical University, 880 Kita-kobayashi, Mibu, Tochigi 321-0293 Japan.
Kazuhiro Kurasawa3Department of Rheumatology, Dokkyo Medical University, 880 Kita-kobayashi, Mibu, Tochigi 321-0293 Japan.
Takeshi Fukuda2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kita-kobayashi, Mibu, Tochigi 321-0293 Japan.
Yasutsugu Fukushima1Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama 343-8555 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.

methodsTwenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.

resultsSixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days,

conclusionAs a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).

Indexed as

Adjustable maintainable dose (AMD)AsthmaBudesonideFormoterolPeak expiratory flow (PEF)Symbicort maintenance and reliever therapy (SMART)

Identifiers

PMID29796287
PMCPMC5963111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.